David Y. Mitchell, Ph.D. Named Nuventra Pharma Sciences' Chief Scientific Officer

DURHAM, N.C.--(BUSINESS WIRE)--Nuventra is pleased to announce that David Y. Mitchell, Ph.D. will serve as the company's new Chief Scientific Officer (CSO). Dr. Mitchell, who has 25 years of pharmaceutical and biotechnology experience in clinical pharmacology, project leadership, and strategic drug development, will be anchoring Nuventra's newest office located in the Greater Denver Area and focusing on pharmacokinetic, pharmacodynamic, and pharmacometric services for our clients.

"I am excited to be part of a dynamic company such as Nuventra"
"I am excited to be part of a dynamic company such as Nuventra," said Dr. Mitchell. Commenting further, Dr. Mitchell stated "All pharmaceutical and biotech companies need the type of services that we provide in PK/PD and population PK to ensure proper dose selection for clinical trials."

"We are thrilled to have Dr. Mitchell as Nuventra's Chief Scientific Officer. We take pride in attracting the industry's leading clinical pharmacology and pharmacokinetic experts and having Dr. Mitchell as our CSO adds to the overall value that Nuventra brings to our clients." said Geoffrey Banks, Ph.D., Nuventra's President and CEO.

Before joining Nuventra, Dr. Mitchell led clinical pharmacology programs at Pfizer and Procter & Gamble Pharmaceuticals. He also served as a global team leader at Pfizer, OSI Pharmaceuticals, and Array Biopharma in the areas of oncology and neuroscience. Dr. Mitchell was the AAPS President in 2012 and chair of the Pharmacokinetics, Pharmacodynamics and Drug Metabolism scientific section in 2004. Recently, Dr. Mitchell was named as the Chair of the AAPS Foundation and appointed to the board of directors for the American Society of Clinical Pharmacology and Therapeutics (ASCPT). Dr. Mitchell has over 60 published manuscripts, chapters, and abstracts primarily in the areas of pharmacokinetics, pharmacodynamics, and metabolism.


Daniel Roy, 919-522-1034
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.